If her follow up presentation Dr. Shah put up a slide @ the 19:40 mark titled:

Take Home Points 

The third bullet point on that slide is titled:

Suggestions of effects on heartfailure and in subgroups 

The bullet point included in that catagory states:

"cautious optimism but not ready for use in patients"

As a Take Home Point this is not a very encouraging indication for those of us who are hoping for FDA approval notwithstanding the failure to meet the primary endpoint.